Company intelligence / Profile preview

Shanghai Medinno Pharmaceutical Technology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

The company has a small pipeline focused on small molecule drugs for immune system diseases, nervous system diseases, congenital disorders, and metabolic disease. Its lead program MDI-1228 has reached Phase I clinical trials for allergic conjunctivitis. No published clinical results are available in the public domain as of January/February/March/April/May of the current year.[1]

Therapeutic areas: ImmunologyEndocrinologyDermatologyRare DiseasesNeurology
Modalities: Small molecule drug[1]
Industry: Biotech

Drug pipeline

1 asset

MDI-1228_mesylate

IND

Indications: Allergic conjunctivitis

Beyond the preview

Go deeper on Shanghai Medinno Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Medinno Pharmaceutical Technology.

Explore the full profile